Evaluation of a commercial Histoplasma antigen detection enzyme immunoassay for the follow-up of histoplasmosis treatment in people living with HIV from Argentina
Medical Mycology · 2024
DOI: 10.1093/mmy/myae121 ↗Kurz gefasst
Evaluationsstudie in der Zeitschrift Medical Mycology, 2024. Verfasst von Fernando A Messina und 5 weiteren Autor:innen. Beteiligte Einrichtung: Unidad Micología, Hospital de Enfermedades Infecciosas Dr. Francisco J. Muñiz, CABA, Argentina. Hauptthemen laut MEDLINE: Histoplasmosis, Antigens, Fungal, Histoplasma, Immunoenzyme Techniques. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben.
Abstract (Originalsprache)
Histoplasmosis poses a significant risk to HIV patients, particularly in regions with limited access to antiretroviral therapy. Antigen detection assays are crucial in these settings for timely diagnosis and treatment, which can reduce mortality. While commercial antigen detection kits have performed well in diagnosing histoplasmosis, their effectiveness in monitoring treatment remains unclear. This study aimed to evaluate the correlation between urine antigen levels and clinical response using the clarus Histoplasma Galactomannan (GM) enzyme immunoassays (EIA) kit. The study followed 27 HIV patients diagnosed with histoplasmosis over 24 weeks, measuring urinary Histoplasma antigen (Ag) levels and clinical outcomes. Patients received amphotericin B as induction therapy, followed by maintenance with itraconazole. Results showed a significant decrease in Ag levels over time, with clinical scores improving in correlation with the decline in Ag levels. Four patients exhibited atypical Ag patterns due to immune reconstitution inflammatory syndrome or issues with itraconazole bioavailability. Despite these challenges, all patients showed improvement by week 24. The findings suggest that the clarus Histoplasma GM EIA kit could be a valuable tool for monitoring and evaluating the response to antifungal therapy in histoplasmosis patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Unidad Micología, Hospital de Enfermedades Infecciosas Dr. Francisco J. Muñiz, CABA, Argentina.
- Immuno-Mycologics (IMMY), Norman, Oklahoma, USA.
- Center of Expertise in Mycology Radboudumc/CWZ, Nijmegen, The Netherlands.
- Studies in Translational Microbiology and Emerging Diseases (MICROS) Research Group, Universidad del Rosario, Bogota, Colombia.
ORCID-Profile: Fernando A Messina, Emmanuel Marin, Diego H Caceres
Zitieren
APA
Messina, F. A., Marin, E., Caceres, D. H., Romero, M., Manrique, M., & Santiso, G. M. (2024). Evaluation of a commercial Histoplasma antigen detection enzyme immunoassay for the follow-up of histoplasmosis treatment in people living with HIV from Argentina. Medical Mycology. https://doi.org/10.1093/mmy/myae121
Vancouver
Messina FA, Marin E, Caceres DH, Romero M, Manrique M, Santiso GM. Evaluation of a commercial Histoplasma antigen detection enzyme immunoassay for the follow-up of histoplasmosis treatment in people living with HIV from Argentina. Medical Mycology. 2024. doi:10.1093/mmy/myae121
BibTeX
@article{Messina2024,
author = {Messina, Fernando A and Marin, Emmanuel and Caceres, Diego H and Romero, Mercedes and Manrique, Mariela and Santiso, Gabriela Maria},
title = {Evaluation of a commercial Histoplasma antigen detection enzyme immunoassay for the follow-up of histoplasmosis treatment in people living with HIV from Argentina},
journal = {Medical Mycology},
year = {2024},
doi = {10.1093/mmy/myae121}
}
EUVIMED